Parent Page: Academic Departments id: 24023 Active Page: Lau Labid:25585



Yuk Kai Lau, MD
B.S. Long Island University, Brooklyn, NY
MD: University of Pennsylvania, Philadelphia, PA

Department of Internal Medicine, Division of Nephrology
Basic Sciences Education Building
941 Stanton L. Young Blvd., Room 130Ab
Oklahoma City, OK 73104

Phone: 405-271-8803

Lau Research Lab

Research interests: Dr. Lau’s research interests are focused on Nephrolithiasis, Severe Hypertension, Electrolyte Disorders, Ion Channels Nephropathy, and Intervention Nephrology.

Selected publications:

1. Lau, K., Wolf, C., Nussbaum, P., Weiner, B., DeOreo, P., Slatopolsky, E., Agus, Z., Goldfarb, S. (1979). Differing effects of acid versus neutral phosphate therapy of hypercalciuria. Kidney international, 16(6), 736-42. PMID: 44888.

2. Lau, K., Thomas, D., Langman, C., Eby, B. (1985). Pathophysiology of spontaneous hypercalciuria in laboratory rats. Role of deranged vitamin D metabolism. The Journal of clinical investigation, 76(2), 420-5. PMID: 3839800. DOI: 10.1172/JCI111988

3. Lau, K., Langman, C. B., Gafter, U., Dudeja, P. K., Brasitus, T. A. (1986). Increased calcium absorption in prehypertensive spontaneously hypertensive rat. Role of serum 1,25-dihydroxyvitamin D3 levels and intestinal brush border membrane fluidity. The Journal of clinical investigation, 78(4), 1083-90. PMID: 3760184. DOI: 10.1172/JCI112664

4. Onopiuk M, Eby B, Nesin V, Ngo P, Lerner M, Gorvin CM, Stokes VJ, Thakker RV, Brandi ML, Chang W, Humphrey MB, Tsiokas L, Lau K. Control of PTH secretion by the TRPC1 ion channel. JCI Insight. 2020 Apr 23;5(8):e132496. doi: 10.1172/jci.insight.132496. PMID: 32213715

Research funding:


Lau, K. (Principal Investigator), 20% Effort, "Mouse Models of Metabolic Syndrome and Diabetic Nephropathy: Studies on Pathogenesis and Therapy," Sponsored by Fraternal Order of Eagles, Non-Profit

Additional Information: The goal of the project is to define the pathobiology of insulin resistance, elucidate the mechanism of diabetic nephropathy, and evaluate novel modalities of therapeutic intervention.

June 1, 2013 - May 31, 2018